Centre for Pharmaceutical Engineering Science wins ICURe Market Validation funding for its innovative 'FastAct' Technology
The team at CPES has recently developed "FastAct" Technology which is a ground breaking invention related to enhanced bioavailability of drugs. FastAct is targeted to address poorly soluble actives in the pharmaceutical, nutraceutical and agrochemical sectors.
Poor water solubility of drugs is a significant challenge for the pharmaceutical industy and around 40% of the New Chemical Entities (NCE) does not reach the market due to low solubility issues. Dr Sachin Korde, a Post-Doctoral Researcher at the CPES was successful in securing £35,000 of funding from Innovate UK which will be used to accelerate the “Innovation to Commercialisation” journey of the “FastAct” Technology. This initial funding will enable CPES to carry out market validation of the research-based business idea and Dr. Korde will also receive intensive support in developing a structured business model.
Technology commercialisation is a major focus of CPES. CPES has recently also been awarded ICURe funding for its SelfGel technology.